Connect to other sites within the UBM Medica Network
Want to maximize the benefits and reduce potential harms of cervical cancer screening? Try these 4 strategies.
FDA Update: Bevacizumab Is Approved for Cervical Cancer
The FDA has approved bevacizumab (Avastin) for treating persistent, recurrent, or metastatic cervical cancer after studies show gains in overall survival.
Already Had Sex? The HPV Vaccine Still Has Value
The optimal time to get the HPV vaccine is before a first sexual encounter. But getting the vaccine after still offers significant protection against cervical dysplasia.
Cervical Cancer Screening Guideline Update
In light of the recent FDA approval of HPV testing for women as a screening method for cervical cancer, we discuss changing guidelines with two experts.
Pelvic Exams Have Value: Does Skipping Them Put Women at Risk?
The American College of Physicians (ACP) recommends against pelvic exams in asymptomatic, nonpregnant, adult women. Some say this is faulty logic. What say you?
FDA Approves HPV Test for Primary Cervical Cancer Screening
The FDA has approved an HPV DNA test to be used as a primary screening method for cervical cancer in women 25 and older. The test can also give insight into future risk of cervical cancer.
Back to Basics: The Well-Woman Visit
Don’t let time constraints and large patient loads prevent you from providing a thorough well-woman visit. Are you covering all the bases?
FDA Panel: HPV Test Can Replace Pap for Cervical Cancer Screening
An FDA panel has recommended that a DNA test that screens for HPV in women can replace the standard Pap smear as a first-line primary cervical cancer screening test.
By clicking Accept, you agree to become a member of the UBM Medica Community.